No profile data available.
Addex Therapeutics Ltd (ADXN) is a healthcare company in the poison treatment pharmaceuticals industry, based in Geneva, Switzerland, with about 3 full-time employees.
It reported revenue of 29,972 CHF for fiscal year 2025, down 92.6% from fiscal year 2024, and net income of -6.73 million CHF. Its market capitalization was $5.64 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.
Addex Therapeutics reported 29,972 CHF in revenue for fiscal year 2025, down 92.6% from 404,102 CHF in fiscal year 2024.
$5.64 million as of October 9, 2026.
Listed companies of a similar size in the same industry (poison treatment pharmaceuticals) include Fennec Pharmaceuticals Inc. (FENC), Anebulo Pharmaceuticals, Inc. (ANEB), Adial Pharmaceuticals, Inc. (ADIL), Clearmind Medicine Inc. (CMND).